The PROSPER trial (pravastatin in elderly individuals at risk of vascular disease) included 5 804 participants and reported a 19% decrease in the risk of coronary artery disease, but no significant increases or decreases in incident T2D ( The JUPITER trial (Justification for the Use of Statins in Prevention: Intervention Trial Evaluating Rosuvastatin) randomly assigned 17 802 men and women to rosuvastatin 20 mg/daily
Duration of Effect: 6-12 months Storage: Sealed, unopened vials at room temperature (1~30C) Shelf life: 2 years from manufacturing date Manufacturer: Daehan NewPharm, Co., Ltd
2.3 Metabolic pathway and statistical analyses Quantitative enrichment analysis of 258 detected metabolites was utilized for pathway analysis employing the web-based MetaboAnalyst 2.0 software (Xia and Wishart 2011)
10.1007/s13669-023-00350-1 Curr Obstet Gynecol Rep
People typically report losing 15-20% of their body weight on semaglutide (like Ozempic/Wegovy) or even more on tirzepatide (Mounjaro/Zepbound) over a period of 6-18 months
These changes are often unexpected and frustrating, especially for women whove maintained a stable weight most of their adult life
